Sign in

CIK 0001782223

  • Emerging growth company

Pyxis Oncology, Inc.

Sign in to watch
Ticker
PYXS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
831160910
Phone
+1 617-221-9059
Business address
321 HARRISON AVENUE, BOSTON, MA, 02118
  1. 4 Grant or award Director acquired 35,219 shares (grant or award)
  2. 4 Grant or award Director acquired 38,741 shares (grant or award)
  3. 4 Grant or award Director acquired 38,741 shares (grant or award)
  4. 4 Derivatives Options or other derivatives
  5. 4 Grant or award SVP, Chief Accounting Officer acquired 131,484 shares (grant or award)
  6. 4 Derivatives Options or other derivatives
  7. 3 Insider Initial Statement of Ownership
  8. 4 Derivatives Options or other derivatives
  9. 3 Insider Initial Statement of Ownership
  10. 4 Shares withheld for taxes CFO and COO gave up 36,949 shares (to pay taxes)
  11. 4 Grant or award Chief Accounting Officer acquired 40,000 shares (grant or award)
  12. 4 Open-market buy CFO and COO bought 8,000 shares at $1.87 ($14,960)
  13. 4 Open-market buy Chief Accounting Officer bought 2,500 shares at $1.87 ($4,675)
  14. 4 Open-market buy CFO and COO bought 6,426 shares at $1.85 ($11,868)
  15. 4 Derivatives Options or other derivatives
  16. 4 Open-market buy Chief Accounting Officer bought 5,000 shares at $1.77 ($8,850)
  17. 4 Open-market buy CFO and COO bought 12,000 shares at $1.67 ($20,044)
  18. 4 Open-market buy Chief Accounting Officer bought 2,500 shares at $1.74 ($4,349)
  19. 4 Open-market buy CFO and COO bought 5,000 shares at $1.74 ($8,695)
  20. 4 Open-market sale President and CEO sold 8,641 shares at an average $2.10 ($18,161)

Page 3 of 7 · 126 filings